Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.

Minoxidil is showing noticeable hair regrowth, but users suggest adding finasteride for better results and longer-lasting effects. Concerns about finasteride's side effects are discussed, but many users report minimal issues.

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A 31-year-old is happy with hair regrowth and thickening after using 0.5 mg dutasteride daily and 5% topical minoxidil. Initial results appeared in six months, with continued improvement over time.

Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.

Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.

The user has been using oral finasteride and topical minoxidil for years without success and is seeking alternative treatments. Suggestions include switching to oral minoxidil, adding dutasteride, trying topical treatments, or considering microneedling.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Oral minoxidil is effective for hair loss but may cause side effects like increased heart rate and edema. Finasteride is recommended, with dutasteride as an alternative if needed.

A 27-year-old actor shared his positive experience with two hair transplant surgeries, highlighting the importance of customization and detail for a natural look. He is taking finasteride to prevent future hair loss.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The user shares a positive experience with Dutasteride for hair loss, noting increased hair density and minimal side effects after switching from Finasteride. They prefer oral Dutasteride and avoid Minoxidil due to its inconvenience and potential risks.

Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.

A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

Minoxidil and Nizoral alone are unlikely to stop hair loss effectively, as they do not address the root cause, which is often DHT. Many users suggest incorporating a 5AR inhibitor like finasteride or dutasteride for better results, despite concerns about potential side effects.

Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.

Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.

Low-dose oral minoxidil is a safe and effective hair loss treatment with fewer side effects than previously feared. Users often prefer it over topical minoxidil for better results, though some experience side effects like increased body hair and cardiovascular issues.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A physician experienced hair thickening and new growth using microneedling and minoxidil, but stopped using topical finasteride due to side effects like reduced libido and erectile dysfunction. The physician plans to continue with microneedling and minoxidil, considering finasteride nonessential for cosmetic purposes.